Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this randomized clinical trial is to evaluate the efficacy and safety of the
alpha adrenergic blocker Alfuzosin (Uroxatral) in men with relatively new onset of chronic
prostatitis/chronic pelvic pain syndrome (CP/CPPS). Alfuzosin is a once daily (10 mg
capsule), FDA approved medication for an indication in benign prostatic hyperplasia (BPH).
The effectiveness of alfuzosin in improving lower urinary tract symptoms in patients with BPH
has been documented in a number of placebo-controlled studies. A number of small studies have
also suggested that alfuzosin ameliorates CP/CPPS symptoms through a similar alpha-blockade
mechanism. This study will enable further testing of this hypothesis
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)